Alembic Ltd (ALEMBICLTD) is currently trading at 90.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alembic Limited is a diversified Indian industrial company principally engaged in manufacturing active pharmaceutical ingredients (APIs) and developing premium residential real estate projects, with manufacturing facilities in Vadodara and Solan and a history dating to 1907; the business now blends a legacy API operation with a sizable real estate development arm that materially drives consolidated earnings. The December 2025 quarter consolidated results show total income of Rs.7,665 lakhs and revenue from operations of Rs.7,434 lakhs, with real estate contributing the bulk of operating revenue; however, Other Income has swung materially quarter‑to‑quarter (notably Rs.6,492 lakhs in Sep 2025), producing significant volatility in reported profit before tax and total comprehensive income for Alembic Limited. Segment profitability is skewed to real estate: Q3 real estate segment profit was Rs.2,385 lakhs versus API segment profit of Rs.214 lakhs, demonstrating Alembic Limited’s real estate projects currently deliver disproportionate operating profits while API operations remain smaller but stable contributors to the consolidated result. Alembic Limited disclosed contingent and provisioning items that are important for risk assessment: a longstanding electricity duty dispute with aggregate principal provisions previously recognised and a Rs.35 crore deposit with the Supreme Court, plus a provisional labour code provision of Rs.143.72 lakhs for the quarter, each influencing Alembic Limited’s near‑term cash and expense profile.

Over the past 52 weeks, Alembic Ltd has traded between a low of ₹70.46 and a high of ₹117.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alembic Ltd has a market capitalization of approximately 2,362.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alembic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.08 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,362.39 Cr, Alembic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alembic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alembic Ltd is 19.08. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit was reported at ₹157 crore, down about 12% YoY.

Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit for the quarter was reported at ₹157 crore (also cited around ₹156 crore in one disclosure).

Alembic said it received USFDA approval for its generic Lamotrigine tablets used to treat seizures, with an ANDA therapeutically equivalent to GlaxoSmithKline’s Lamictal.

Dapagliflozin is a medication used to treat type 2 diabetes and reduce the risk of heart failure. The final USFDA approval is significant for Alembic as it allows the company to launch a generic version in the U.S. market, which is estimated to be worth over $10 billion, and includes a 180-day shared exclusivity period.